GlassScriptPhysician profile
John Barnwell Kerrison
NPI 1952416257
$12,102.37
in general payments reported to CMS, 2019-2025
30 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $851 · 2021: $1,285 · 2022: $6,071 · 2023: $1,285 · 2024: $692 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,811.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $7,045.91 | 2019-2022 | |
| Genentech USA, INC. | $1,341.48 | 2019-2025 | Vabysmo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $757.02 | 2021-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $440.17 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $361.53 | 2022-2025 | Syfovre |
| Abbvie INC. | $273.45 | 2022-2025 | |
| Coherus Oncology, INC. | $248.10 | 2023-2024 | |
| Biogen, INC. | $210.05 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $169.92 | 2019-2021 | |
| Allergan, INC. | $157.12 | 2019-2021 | |
| Alcon Vision LLC | $154.23 | 2024-2025 | Constellation, Rocklatan |
| Genentech, INC. | $150.00 | 2023 | Vabysmo |
| Harrow Eye, LLC | $146.23 | 2024-2025 | Iheezo |
| Eyepoint US, INC. | $127.29 | 2023 | |
| Notal Vision, INC. | $103.87 | 2024 | Foresee Home |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $82.78 | 2021 | |
| Mallinckrodt Enterprises LLC | $71.47 | 2019 | |
| Alimera Sciences, INC. | $53.46 | 2022-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $42.78 | 2023 | |
| Dutch Ophthalmic, USA | $37.76 | 2021 | |
| Kala Pharmaceuticals, INC. | $30.64 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $21.81 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.85 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.27 | 2022 | |
| Travere Therapeutics, INC. | $18.96 | 2020 | |
| Horizon Therapeutics Plc | $16.22 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,083.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kerrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.